KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zimmer Biomet Holdings (ZBH) Gains from Sales and Divestitures (2022 - 2025)

Zimmer Biomet Holdings has reported Gains from Sales and Divestitures over the past 6 years, most recently at $683000.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $683000.0 for Q4 2025, up 68.64% from a year ago — trailing twelve months through Dec 2025 was $683000.0 (up 68.64% YoY), and the annual figure for FY2025 was $683000.0, up 68.64%.
  • Gains from Sales and Divestitures for Q4 2025 was $683000.0 at Zimmer Biomet Holdings, up from $405000.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for ZBH hit a ceiling of $683000.0 in Q4 2025 and a floor of $168000.0 in Q4 2022.
  • Median Gains from Sales and Divestitures over the past 4 years was $335000.0 (2023), compared with a mean of $380250.0.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 52.83% in 2024 and later surged 68.64% in 2025.
  • Zimmer Biomet Holdings' Gains from Sales and Divestitures stood at $168000.0 in 2022, then soared by 57.74% to $265000.0 in 2023, then soared by 52.83% to $405000.0 in 2024, then surged by 68.64% to $683000.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $683000.0 (Q4 2025), $405000.0 (Q4 2024), and $265000.0 (Q4 2023) per Business Quant data.